Real-World First-Line Maintenance Niraparib Monotherapy Use Following Chemotherapy Plus Bevacizumab: The SW1TCH Study.
Bobbie J RimelTirza Areli Calderón BoyleSara BurnsJonathan LimJohn HartmanLinda KalilaniJeanne M SchilderJean A HurteauAmanda GolembeskyPublished in: Oncology and therapy (2024)
This real-world study provided insights into switch maintenance with 1LM niraparib monotherapy, which may be a viable treatment option for patients with advanced OC.